- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Paediatric psoriasis
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1232KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 138KB)
Secukinumab – November 2021
Secukinumab: Injection 75 mg in 0.5 mL pre-filled syringe, Injection 150 mg in 1 mL pre-filled pen, Injection 300 mg in 2 mL pre-filled pen, Injection 300 mg in 2 mL pre-filled syringe; Cosentyx®
Last updated
4 March 2022
